Efficacy and Safety of SGLT2 Inhibitor on Insulin Resistance and Hyperglycemia in Werner Syndrome—A Case Report

This case report highlights the successful use of dapagliflozin, an SGLT2 inhibitor, in a 48-year-old man with Werner syndrome (WS) to improve glycemic control and insulin resistance. Despite initial treatment with pioglitazone and metformin, insulin resistance persisted, but the addition of dapagliflozin significantly improved glycemic control, maintaining HbA1c levels under 7% over four years without adverse events. The report suggests that dapagliflozin may reduce visceral fat, improve insulin sensitivity, and offer renal protection, making it a promising treatment for diabetes in WS patients. The potential role of the αKlotho gene in anti-aging and renal protection is also noted, although not specifically measured in this case.